drugset / Trial / NCT00469027
Pulmonary Hypertension: Assessment of Cell Therapy
Phase 1
Completed
7 enrolled
Northern Therapeutics
Sir Mortimer B. Davis - Jewish General Hospital · collabUnity Health Toronto · collab
NaSingle-groupOpen-label
Summary
The primary objective is to establish the safety of autologous progenitor cell-based gene therapy of heNOS in patients with severe Pulmonary Arterial Hypertension(PAH) refractory to conventional treatment.
Timeline
- Start
- 2006-05
- Primary completion
- 2012-07
- Completion
- 2012-07
Publications
- Granton J, Langleben D, Kutryk MB, Camack N, Galipeau J, Courtman DW, Stewart DJ. Endothelial NO-Synthase Gene-Enhanced Progenitor Cell Therapy for Pulmonary Arterial Hypertension: The PHACeT Trial. Circ Res. 2015 Sep 11;117(7):645-54. doi: 10.1161/CIRCRESAHA.114.305951. Epub 2015 Jul 20.
- O'Connell C, O'Callaghan DS, Humbert M. Novel medical therapies for pulmonary arterial hypertension. Clin Chest Med. 2013 Dec;34(4):867-80. doi: 10.1016/j.ccm.2013.08.002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | eNOS transfected EPCs | Cell therapy | 7e+06 cells | Other |
| Subject | eNOS transfected EPCs | Cell therapy | 5e+07 cells | Other |